Atherosclerosis · 2018
Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brunham Liam R, Ruel Isabelle, Khoury Etienne, Hegele Robert A, Couture Patrick, Bergeron Jean, Baass Alexis, Dufour Robert, Francis Gordon A, Cermakova Lubomira, Mancini G B John, Brophy James M, Brisson Dianne, Gaudet Daniel, Genest Jacques
Аннотация
BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is under-diagnosed and under-treated in most of the world, including Canada. National registries play a key role in identifying patients with FH, understanding gaps in care, and advancing the science of FH to better treat these patients.
METHODS: FH Canada has established a national registry across 19 academic sites acting as "hubs" in Canada to increase awareness and access to standard-of-care therapies.
RESULTS: To-date, more than 3000 patients with FH have been entered into a secure, web-based database. Early outcomes of this initiative include a greater understanding of treatment gaps for patients with FH in Canada, the development of a new, simplified Canadian definition of FH, and tools to aid in the diagnosis of FH, including imputation of baseline levels of LDL cholesterol.
CONCLUSIONS: As the national registry expands in size and scope, further learning will emerge with ultimate benefit for the diagnosis and treatment of FH in Canada.
METHODS: FH Canada has established a national registry across 19 academic sites acting as "hubs" in Canada to increase awareness and access to standard-of-care therapies.
RESULTS: To-date, more than 3000 patients with FH have been entered into a secure, web-based database. Early outcomes of this initiative include a greater understanding of treatment gaps for patients with FH in Canada, the development of a new, simplified Canadian definition of FH, and tools to aid in the diagnosis of FH, including imputation of baseline levels of LDL cholesterol.
CONCLUSIONS: As the national registry expands in size and scope, further learning will emerge with ultimate benefit for the diagnosis and treatment of FH in Canada.
Предметные рубрики MeSH
AdultAnticholesteremic AgentsBiomarkersCanadaCardiovascular DiseasesCholesterol, LDLDatabases, FactualDown-RegulationDrug Therapy, CombinationFemaleGenetic Predisposition to DiseaseHeredityHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipoproteinemia Type IIMaleMiddle AgedPCSK9 InhibitorsPedigreePhenotypePrevalenceProprotein Convertase 9RegistriesRisk AssessmentRisk FactorsSerine Proteinase InhibitorsTime FactorsTreatment OutcomeYoung Adult